LINCOCIN SOLUTION

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

LINCOMYCIN (LINCOMYCIN HYDROCHLORIDE)

Tilgængelig fra:

PFIZER CANADA ULC

ATC-kode:

J01FF02

INN (International Name):

LINCOMYCIN

Dosering:

300MG

Lægemiddelform:

SOLUTION

Sammensætning:

LINCOMYCIN (LINCOMYCIN HYDROCHLORIDE) 300MG

Indgivelsesvej:

INTRAMUSCULAR

Enheder i pakken:

2ML

Recept type:

Prescription

Terapeutisk område:

LINCOMYCINS

Produkt oversigt:

Active ingredient group (AIG) number: 0105826002; AHFS:

Autorisation status:

CANCELLED POST MARKET

Autorisation dato:

2016-05-06

Produktets egenskaber

_ _
_LINCOCIN (lincomycin hydrochloride) Product Monograph _
_Page 1 of 20_
PRODUCT MONOGRAPH
PR
LINCOCIN
®
LINCOMYCIN INJECTION USP
300 MG/ML
ANTIBIOTIC
Pfizer Canada Inc.
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Preparation:
17 September 2003
Date of Revision:
8 June 2018
Control No. 208095
®
Pharmacia & Upjohn Company LLC
Pfizer Canada Inc., Licensee

Pfizer Canada Inc. 2018
_ _
_LINCOCIN (lincomycin hydrochloride) Product Monograph _
_Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.................................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
3
WARNINGS AND PRECAUTIONS
...........................................................................................
4
ADVERSE REACTIONS
..............................................................................................................
6
DRUG INTERACTIONS
..............................................................................................................
7
DOSAGE AND ADMINISTRATION
..........................................................................................
7
OVERDOSAGE
.............................................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
8
STORAGE AND STABILITY
......................................................................................................
9
DOSAGE FORMS, COMPOSITION AND
PACKAGING....................................................... 9
PART II: SCIENTIFIC INFORMATION
..............................................................................
10
PHARM